Skip to main content
. 2023 Mar 10;64(3):21. doi: 10.1167/iovs.64.3.21

Table 1.

Clinical Characteristics of Participants

Group 1 MvD+ PPA– (n = 25) Group 2 MvD+ PPA+ (n = 75) Group 3 MvD– PPA+ (n = 40) Group 4 MvD– PPA– (n = 57) P Value Post Hoc*
Age (years) 50.4 ± 14.4 61.0 ± 8.8 58.8 ± 11.5 52.6 ± 13.5 <0.001 1=4<3=2
Male/female (n) 14/11 23/52 20/20 24/33 0.072 n/a
Baseline IOP (mm Hg) 17.8 ± 5.1 18.1 ± 5.9 17.7 ± 5.0 18.2 ± 5.3 0.958 n/a
IOP at OCTA exam (mm Hg) 12.2 ± 2.2 11.9 ± 1.6 12.2 ± 2.0 12.9 ± 2.6 0.080 n/a
Baseline global RNFLT (µm) 79.4 ± 16.2 77.9 ± 12.7 80.9 ± 12.6 81.1 ± 14.6 0.530 n/a
Baseline VF MD (dB) −5.09 ± 5.93 −6.03 ± 6.17 −3.86 ± 4.66 −3.60 ± 3.93 0.042 2<3=4
Any episode of DH, n (%) 8 (32.0) 26 (34.7) 11 (27.5) 13 (22.8) 0.504 n/a
Recurrent DH, n (%) 4 (16.0) 15 (20.0) 6 (15.0) 6 (10.5) 0.529 n/a
Axial length (mm) 24.09 ± 1.05 23.76 ± 1.06 23.93 ± 1.34 24.23 ± 1.26 0.141 n/a
Central corneal thickness (µm) 564.7 ± 46.8 554.5 ± 35.3 553.4 ± 33.7 553.5 ± 36.8 0.609 n/a
Area of MvD (mm2) 0.23 ± 0.16 0.27 ± 0.15 n/a n/a 0.158 n/a
Systolic BP (mm Hg) 126.5 ± 14.3 127.8 ± 17.4 128.7 ± 16.4 127.9 ± 18.0 0.971 n/a
Diastolic BP (mm Hg) 70.0 ± 11.4 71.5 ± 11.8 76.0 ± 13.0 76.2 ± 12.5 0.052 1=2<4
Sleep apnea, n (%) 1 (4.0) 1 (1.3) 0 (0.0) 4 (7.0) 0.167 n/a
Migraine, n (%) 4 (16.0) 12 (16.0) 2 (5.0) 2 (3.5) 0.050 2>4
Cold extremity, n (%) 8 (32.0) 23 (30.7) 4 (10.0) 7 (12.3) 0.008 1=2>3=4
Diabetes mellitus, n (%) 3 (12.0) 11 (14.7) 11 (27.5) 12 (21.1) 0.300 n/a
Systemic hypertension, n (%) 5 (20.0) 32 (42.7) 18 (45.0) 22 (38.6) 0.161 n/a
Cardiac arrhythmia, n (%) 1 (4.0) 1 (1.3) 4 (10.0) 3 (5.3) 0.210 n/a
Asthma, n (%) 2 (8.0) 3 (4.0) 2 (5.0) 1 (1.8) 0.603 n/a
Smoking, n (%) 11 (44.0) 18 (24.0) 19 (33.3) 0.138 n/a
*

LSD post hoc test.

Statistically significant values are shown in bold.

DH, disc hemorrhage; MD, mean deviation; PPA, β-parapapillary atrophy; RNFLT, retinal nerve fiber layer thickness.